Uroflo0.4 mg

Uroflo 0.4 mg is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) in adult men, such as difficulty urinating, weak urinary stream, urinary frequency, urgency, and incomplete bladder emptying.

• FDA-approved / established use: Relief of functional (dynamic) obstructive symptoms of BPH by relaxing smooth muscle in the bladder neck and prostate.
• Adjunct / combination use: Used together with a 5-alpha-reductase inhibitor (e.g. dutasteride or finasteride) in men with an enlarged prostate for more comprehensive symptom control and reduction in risk of BPH progression.
• Off-label use: Sometimes used off-label to facilitate passage of ureteral (kidney) stones as "medical expulsive therapy," though this is not an FDA-approved indication.

Uroflo 0.4 mg is not indicated for the treatment of hypertension and is not indicated for use in women or children, as BPH is a condition specific to the male prostate gland.

Each capsule contains Uroflo 0.4 mg as the active ingredient, commonly available as a modified-release (sustained-release) capsule of 0.4 mg strength. Inactive ingredients vary by manufacturer and typically include fillers, binders, and a coating to control the release rate of the drug.

Uroflo 0.4 mg is a selective alpha-1 adrenergic receptor antagonist used specifically for the management of urinary symptoms associated with benign prostatic hyperplasia (BPH), a common non-cancerous enlargement of the prostate gland in older men. Unlike non-selective alpha blockers, Uroflo 0.4 mg preferentially targets alpha-1A receptors, which are concentrated in the smooth muscle of the prostate and bladder neck, making it effective for urinary symptom relief with a comparatively lower risk of blood-pressure-related side effects than older, non-selective agents.

Uroflo 0.4 mg is formulated as a modified-release capsule to be taken once daily, and it does not shrink the prostate gland itself; it works by relaxing muscle tissue to improve urine flow.

Uroflo 0.4 mg belongs to the therapeutic class of selective alpha-1A adrenergic receptor antagonists (alpha blockers), used for the symptomatic treatment of benign prostatic hyperplasia (BPH).

Uroflo 0.4 mg is a selective antagonist of alpha-1A adrenoceptors, which are the predominant alpha-1 receptor subtype found in the smooth muscle of the human prostate, bladder neck, and prostatic capsule. By blocking these receptors, Uroflo 0.4 mg relaxes smooth muscle in the lower urinary tract, reducing resistance to urine flow and improving symptoms of BPH such as weak stream, hesitancy, and incomplete emptying, without significantly affecting detrusor (bladder muscle) contraction.

Pharmacokinetics: Uroflo 0.4 mg is well absorbed (about 90%) after oral administration under fasting conditions, with peak plasma concentrations reached in approximately 4-5 hours (delayed and reduced somewhat if taken with food, hence the recommendation to take it consistently after the same meal). It is extensively bound to plasma proteins (94-99%) and is metabolized in the liver, predominantly via CYP3A4 and CYP2D6 enzymes, with less than 10% excreted unchanged in urine. The elimination half-life is approximately 9-15 hours at steady state with modified-release formulations.

Uroflo 0.4 mg should be taken orally, once daily, approximately 30 minutes after the same meal each day. Swallow the capsule whole with a glass of water; do not crush, chew, or open it.

• Strong CYP3A4 inhibitors (e.g. ketoconazole, ritonavir, clarithromycin): Can significantly increase plasma concentrations of Uroflo 0.4 mg, raising the risk of hypotension; concomitant use should be avoided, particularly in patients with renal or hepatic impairment.
• Other alpha-1 blockers: Concomitant use with other alpha-adrenergic antagonists is not recommended, as it may cause additive hypotensive effects.
• PDE5 inhibitors (e.g. sildenafil, tadalafil): Concurrent use may increase the risk of symptomatic postural hypotension; caution and dose stability are advised before adding a PDE5 inhibitor.
• CYP2D6 inhibitors (e.g. paroxetine): May increase exposure to Uroflo 0.4 mg; monitor for increased side effects.
• Warfarin: Interaction data are limited; caution and monitoring are advised if used concomitantly.
• Cimetidine: May increase plasma levels of Uroflo 0.4 mg.

The most commonly reported side effects of Uroflo 0.4 mg (occurring in ≥2% of patients and more often than with placebo) include:

• Headache
• Dizziness
• Abnormal ejaculation (including retrograde/decreased ejaculation)
• Rhinitis (runny or stuffy nose)
• Asthenia (weakness/fatigue)
• Back pain
• Infection (e.g. upper respiratory infection)

Less common but important effects include postural (orthostatic) hypotension and syncope, particularly with the first few doses (see Precautions and Warnings), and rare reports of priapism (a prolonged, painful erection requiring emergency treatment) and intraoperative floppy iris syndrome during cataract surgery.

Uroflo 0.4 mg is not indicated for use in women, as benign prostatic hyperplasia is a condition of the male prostate gland. There is no clinical data on the use of Uroflo 0.4 mg during human pregnancy or lactation, and it should not be used in pregnant or breastfeeding women. If exposure occurs, or if used for an unapproved indication in a woman who is pregnant or breastfeeding, a physician should be consulted promptly, and the drug should be used only if clearly needed and no safer alternative exists, weighing potential risk to the fetus or infant against any potential benefit.

Orthostatic Hypotension and Syncope

As with other alpha-1 blockers, Uroflo 0.4 mg can cause a marked drop in blood pressure on standing, leading to dizziness, lightheadedness, or fainting (syncope), especially after the first dose or with dose increases. Patients should be cautioned to sit or lie down at the first sign of dizziness and to avoid driving, operating machinery, or performing hazardous tasks until they know how they respond to the medicine.

Intraoperative Floppy Iris Syndrome (IFIS)

A variant of small pupil syndrome, IFIS, has been observed during cataract and glaucoma surgery in some patients treated with Uroflo 0.4 mg or previously treated with it (even after stopping the drug). Patients scheduled for cataract or glaucoma surgery must inform their ophthalmologist about current or prior use of Uroflo 0.4 mg before the procedure, as the surgeon may need to modify the surgical technique.

Priapism

Rare cases of prolonged, painful erection (priapism) have been reported with alpha-1 blockers including Uroflo 0.4 mg. This is a medical emergency; patients should seek immediate treatment if an erection persists for more than 4 hours.

Not for Hypertension

Uroflo 0.4 mg has not been evaluated for, and should not be used for, the treatment of high blood pressure.

Overdose of Uroflo 0.4 mg may result in acute hypotension, dizziness, and syncope due to excessive alpha-adrenergic blockade. If overdose is suspected, seek immediate medical attention or contact a poison control center right away. Management is generally supportive: the patient should be placed in a recumbent (lying down) position to restore blood pressure and cerebral blood flow; intravenous fluids and, if needed, vasopressor support may be given by medical professionals. Because Uroflo 0.4 mg is highly protein-bound, dialysis is unlikely to be of significant benefit. Do not attempt to manage a suspected overdose at home without medical guidance.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Women

Uroflo 0.4 mg is not indicated for use in women.

Pediatric Patients

Safety and efficacy of Uroflo 0.4 mg in pediatric patients have not been established. Clinical trials in children did not demonstrate benefit over placebo, and its use in this population is not recommended.

Geriatric Patients

No significant differences in effectiveness were observed in elderly patients compared with younger adults; however, elderly patients may have increased individual sensitivity to the blood-pressure-lowering effects, so the usual caution regarding orthostatic hypotension applies (see Precautions and Warnings).

Renal and Hepatic Impairment

See Dosage and Administration for renal and hepatic dosing considerations.

Uroflo 0.4 mg is typically used as a long-term, ongoing therapy for chronic BPH symptom control, as symptoms generally recur if the medication is stopped. Response to treatment is usually assessed 2-4 weeks after starting or after a dose increase. Duration should be determined by the prescribing physician based on symptom control and tolerability, with periodic reassessment.

Alpha-1 adrenergic receptor antagonist (alpha blocker); genitourinary smooth muscle relaxant.

Uroflo 0.4 mg selectively blocks alpha-1A adrenergic receptors located in the smooth muscle of the prostate, prostatic capsule, and bladder neck. This blockade relaxes the smooth muscle, reducing dynamic urethral resistance and improving urine flow and BPH symptoms, without primarily affecting blood vessel tone to the same degree as non-selective alpha blockers.

Uroflo 0.4 mg is not approved for use in children. Safety and efficacy have not been established in pediatric patients, and clinical studies in children failed to show benefit over placebo; therefore its use in this population is not recommended.